We discuss gene therapy pricing and reimbursement, manufacturing methods, analytical analysis, and k...
Read moreOur market access experts cover the changes to the joint EU HTA process that occurred in 2022 and wh...
Read moreWe discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreThe pricing dynamics of biosimilars, depends on the type of biosimilar, its indication and the chann...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreOur Market Access Analysts discuss the proposed changes to CAR-T reimbursement in the US and conside...
Read moreDigital therapeutics: a growing market The year is 2008 and Apple have just added a new category to ...
Read moreIntroduction Digital therapeutics (DTx) or digital health technologies (DHTs) are defined as product...
Read more